Aclaris Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States, with headquarters in Wayne, Pennsylvania. The company has evolved from a dermatology-focused specialty biotech into a clinical-stage developer of immuno-inflammatory therapies. For investors, ACRS is best viewed as a small-cap biotech with a high-risk/high-upside profile, where valuation is primarily driven by clinical execution, pipeline breadth, and capital discipline rather than current commercial sales. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025)) Aclaris’ core business is built around internal drug discovery and early development, with particular expertise in kinase inhibition and immune-inflammatory biology. The company highlights its proprietary KINect platform and a pipeline that spans both small molecules and biologics. It also operates Confluence Discovery Technologies, a full-service discovery and early-development CRO, which supports external research relationships and broadens the company’s scientific capabilities. This structure gives Aclaris both a pipeline engine and a research-services component, although the investment case remains overwhelmingly centered on drug development outcomes. ([aclaristx.com](https://www.aclaristx.com/overview/?utm_source=openai)) The most visible asset is ATI-052, a novel anti-TSLP/IL-4Rα bispecific antibody that the company describes as potentially first-in-class. In 2026, Aclaris reported positive interim Phase 1a results and advanced into Phase 1b proof-of-concept studies in atopic dermatitis and asthma. The company expects top-line readouts from both Phase 1b studies in the second half of 2026, and it has also signaled plans to move ATI-052 into a Phase 2b program, initially in asthma, later in 2026. These updates are important because they help validate the program’s translational potential and expand the range of possible indications. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025)) A second major program is ATI-2138, an oral dual inhibitor of ITK and JAK3. Aclaris has recently identified lichen planus as the lead indication for this asset and intends to launch a phased basket study covering the most common lichen planus subtypes, including erosive mucosal, cutaneous, and lichen planopilaris. The company argues that the opportunity in lichen planus is meaningful because there are currently no FDA-approved therapies, underscoring the unmet medical need. Aclaris is also evaluating additional inflammatory and alopecia-related indications linked to this mechanism of action. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-positive-full-top-line-first)) Competitive positioning is centered on differentiation rather than scale. Aclaris does not compete as a commercial dermatology platform with large marketed revenues; instead, it competes as a focused clinical-stage innovator aiming at under-served immune-inflammatory diseases. Its geographic footprint is primarily U.S.-based, with operations centered in Pennsylvania and select collaborations or licensing arrangements abroad. The latest corporate update reported cash, cash equivalents and marketable securities of $151.4 million at December 31, 2025 and stated that this should fund operations into the second half of 2028, excluding certain future trial costs and business development activity. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025)) Recent corporate milestones include the February 2026 year-end results release, ongoing Phase 1b enrollment for ATI-052 in both atopic dermatitis and asthma, and the company’s continued expansion of its immunology pipeline. For investors in France, Belgium, and Switzerland, Aclaris is therefore a classic NASDAQ biotech story: scientifically interesting, clinically driven, and highly sensitive to readouts, partnering decisions, and funding visibility. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025))